Rhenman & Partners Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Rhenman & Partners Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-360,000	Closed	-$13.1M	–	110
2016 Q4	$13.1M	Buy	360,000 +90,000	+33%	+$3.59M	2.5%	7
2016 Q3	$12.4M	Buy	+270,000	New	+$14.1M	1.97%	16
2015 Q3	–	Sell	-92,000	Closed	-$5.44M	–	96
2015 Q2	$5.44M	Buy	92,000 +42,000	+84%	+$2.59M	0.65%	52
2015 Q1	$3.12M	Buy	+50,000	New	+$2.91M	0.53%	66
2014 Q4	–	Sell	-59,000	Closed	-$3.17M	–	93
2014 Q3	$3.17M	Buy	59,000 +34,000	+136%	+$1.8M	0.93%	39
2014 Q2	$1.31M	Sell	25,000 -82,922	-77%	-$4.24M	0.39%	79
2014 Q1	$5.7M	Buy	107,922 +42,922	+66%	+$1.98M	1.71%	13
2013 Q4	$2.6M	Buy	+65,000	New	+$2.56M	1.02%	44

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Rhenman & Partners Asset Management's TEVA Position: Q1 2017 in Review

Rhenman & Partners Asset Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2017, closing a stake of 360,000 shares — an estimated $13.1M sold.

Rhenman & Partners Asset Management first reported a position in TEVA in Q4 2013 and held it in 8 quarters. The position peaked at $13.1M in Q4 2016. 686 funds tracked by Wall St. Rank hold TEVA as of Q1 2017.

Rhenman & Partners Asset Management reported no remaining Teva Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Rhenman & Partners Asset Management sold 360,000 Teva Pharmaceuticals shares in Q1 2017, an estimated $13.1M.
Rhenman & Partners Asset Management first reported a position in Teva Pharmaceuticals in Q4 2013 and held it in 8 quarters.
Rhenman & Partners Asset Management's Teva Pharmaceuticals position peaked at $13.1M in Q4 2016.
686 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2017.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2017, filed 19 Apr 2017.